Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of sacituzumab govitecan plus Q901 in advanced triple-negative breast cancer
KCT0012337Phase 2Not yet recruiting
- Sponsor
- Yonsei University Health System
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, mocaciclib in triple-negative breast cancer (TNBC), sponsored by Yonsei University Health System. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecanmocaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on KCT0012337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012337.